WO2014185542A1 - Composition pharmaceutique pour traiter une vaginite ou une pneumonie - Google Patents

Composition pharmaceutique pour traiter une vaginite ou une pneumonie Download PDF

Info

Publication number
WO2014185542A1
WO2014185542A1 PCT/JP2014/063138 JP2014063138W WO2014185542A1 WO 2014185542 A1 WO2014185542 A1 WO 2014185542A1 JP 2014063138 W JP2014063138 W JP 2014063138W WO 2014185542 A1 WO2014185542 A1 WO 2014185542A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
vaginitis
pneumonia
crotamiton
trichomonas
Prior art date
Application number
PCT/JP2014/063138
Other languages
English (en)
Inventor
Hirokazu Kobayashi
Original Assignee
Pola Pharma Inc.
Nihon Nohyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc., Nihon Nohyaku Co., Ltd. filed Critical Pola Pharma Inc.
Priority to JP2015551899A priority Critical patent/JP2016518306A/ja
Publication of WO2014185542A1 publication Critical patent/WO2014185542A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical composition.
  • the present invention relates to a pharmaceutical composition preferably usable to treat vaginitis (colpitis) and pneumonia.
  • Chlamydia vaginitis for example, it is also reported that about 70% of specimens had the pathogen according to a fixed point investigation performed by a certain public health center in the Tokyo metropolitan area (see, for example, Non-Patent Document 1) . Trichomonas vaginitis as well as Chlamydia vaginitis is also classified into STD. It is said that Trichomonas vaginitis is increased as accompanied with the increase in illicit sexual act in the same manner as Chlamydia vaginitis. Tetracycline and macrolide antibiotics are effective for Chlamydia
  • vaginitis while the therapeutic agent is only metronidazole for Trichomonas vaginitis.
  • metronidazole the response rate is low with respect to the vaginitis, and it is difficult to exterminate protozoa especially in vagina. Therefore, it is inevitable to rely on any vaginal tablet.
  • the efficacy of the vaginal tablet is low to exterminate protozoa from outer labia. In this sense, any therapeutic means, which is effective for Trichomonas vaginitis, has not been obtained in the present
  • pneumonia is caused in most cases by Pneumococci as accompanied, for example, with influenza principally.
  • fungal pneumonia which is caused, for example, by Candida and/or Aspergillus, is rapidly increased in recent years on account of the decrease in immunity by the chemotherapy for cancer or the decrease in immunity by the onset or crisis of AIDS.
  • patients infected with Chlamydia pneumonia are patients infected with Chlamydia pneumonia
  • Trichomonas in the same manner as in vaginitis is observed in pneumonia caused by the microorganism ( s ) of Candida and/or Aspergillus (see, for example, Non-Patent Documents 2 and 3) .
  • Such multiple infection also makes it difficult to perform the medical treatment, in the same manner as in vaginitis .
  • each of Ri and R 2 independently represents hydrogen atom or halogen atom, and Ri and R2 are not simultaneously hydrogen atoms.
  • Non-Patent Document 1 Homepage of Tokyo Metropolitan
  • Non-Patent Document 2 Zdrodowska-Stefanow B, Klosowska WM, Ostaszewska-Puchalska I, Bulhak-Koziol V, Kotowicz B;
  • Non-Patent Document 3 Mittal A, Rastogi S, Reddy BS, Verma S, Salhan S, Gupta E; "Enhanced immunocompetent cells in chlamydial cervicitis.” J Reprod Med. 2004 ;49(8): 671-7; Non-Patent Document 4: Pal C, Bandyopadhyay U.; "Redox- active antiparasitic drugs” Antioxid Redox Signal. 2012; 17 (4) : 555-82.
  • Patent Documents
  • Patent Document 1 JP2004-521102W;
  • Patent Document 3 JP2003-527308W;
  • Patent Document 4 JP08-198773A
  • Patent Document 5 WO2007/102242.
  • the present invention has been made under the
  • an object of which is to enhance the action of the compound represented by the general formula (1) described above and provide a
  • composition effective for pneumonia and vaginitis .
  • composition which includes the compound represented by the general formula (1) described above as an active ingredient and which is effective for pneumonia and vaginitis.
  • the present invention is as follows .
  • a pharmaceutical composition for vaginitis or pneumonia comprising a compound represented by the
  • ⁇ 3> The pharmaceutical composition as defined in ⁇ 1> or ⁇ 2>, wherein a pathogen of vaginitis or pneumonia includes Trichomonas .
  • ⁇ 4> The pharmaceutical composition according to any one of ⁇ 1> to ⁇ 3>, wherein the pharmaceutical composition is in a form of suppository or tablet.
  • composition effective for pneumonia and vaginitis.
  • each the groups represented by R x and R 2 is hydrogen atom or halogen atom.
  • Ri and R 2 are not simultaneously hydrogen atoms.
  • the halogen atom can be preferably exemplified, for example, by chlorine atom, bromine atom, fluorine ' atom, and iodine atom.
  • the group represented by Ri and R 2 is especially preferably a
  • the compound represented by the general formula (1) is especially preferably
  • the compound as described above has the antifungal action, the anti-Trichomonas action, and the anti-Chlamydia action, and it is possible to treat pneumonia and vaginitis caused by multiple infection, with one component. The actions will be explained in Exemplary Tests described ⁇ later on.
  • the compound as described above can be synthesized, for example, in accordance with a method described in JP60- 218387A. That is, 1-cyanomethylimidazole and carbon disulfide are reacted to obtain a compound of (III) which is reacted with a compound of the general formula (II) having a leaving group.
  • a compound of (III) which is reacted with a compound of the general formula (II) having a leaving group.
  • the leaving group as described above can be preferably exemplified, for example, by
  • methanesulfonyloxy group benzenesulfonyloxy group, p- toluenesulfonyloxy group, and halogen atom.
  • Y, Y' represent the leaving groups, and M represents alkali metal.
  • the compound represented by the general formula (1) is contained by 0.1 to 10% by mass, and it is more preferable that the compound
  • the pharmaceutical composition contains crotamiton.
  • crotamiton is contained by 0.1 to 50% by mass, and it is more preferable that crotamiton is contained by 1 to 10% by mass in the pharmaceutical composition of the present invention.
  • crotamiton is contained in an amount of 0.5 to 15 mass times the compound of the general formula (1), and it is more preferable that crotamiton is contained in an amount of 1 to 10 mass times the compound of the general formula (1), for the following reason. That is, if the amount of crotamiton is excessively small, the enhancing effect is not expressed in some cases. If the amount of crotamiton is excessively large, it is difficult to prepare the pharmaceutical preparation in some cases.
  • composition of the present invention The pharmaceutical composition of the present invention.
  • the pharmaceutical composition contains the essential components as described above, and the pharmaceutical composition is usable to perform the treatment for vaginitis or pneumonia.
  • the treatment herein includes, for example, the medical
  • the component represented by the general formula (1) also has the medical treatment effect with respect to protozoa such as Trichomonas or the like and intracellular parasite such as Chlamydia or the like, in addition to fungi such as Candida, Aspergillus or the like. Therefore, the compound represented by the general formula (1) is preferably applied to the infectious disease caused by the pathogen as described above and the multiple
  • the compound also effectively acts on those against which little
  • the countermeasure has been hitherto available, including, for example, the multiple infection of fungus and protozoa, the multiple infection of fungus and intracellular parasite, the multiple infection of protozoa and intracellular parasite, and the multiple infection of fungus, protozoa, and intracellular parasite, which is preferred.
  • the compound is also effective for the single infection of fungus, protozoa, or intracellular parasite.
  • the pharmaceutical composition of the present invention can treat, as the disease to be applied,
  • vaginitis and pneumonia caused by the pathogen of, for example, intracellular parasite, protozoa, and/or fungus (for example, vaginitis and pneumonia diagnosed that the pathogen is intracellular parasite, protozoa, and/or fungus).
  • the pharmaceutical composition of the present invention has the action to enhance the action of the compound of the general formula (1) exerted on protozoa such as Trichomonas or the like. Therefore, the pharmaceutical composition of the present invention is preferably applicable to vaginitis and pneumonia in which the pathogen includes Trichomonas .
  • the "pharmaceutical composition for vaginitis and pneumonia caused by the pathogen including Trichomonas of the present invention” can be applied to vaginitis and pneumonia in which the pathogen is protozoa and vaginitis and pneumonia in which the pathogen is protozoa and intracellular parasite and/or fungus.
  • the "pharmaceutical composition for vaginitis and pneumonia caused by the pathogen including Trichomonas of the present invention” to vaginitis and pneumonia caused by the pathogen of fungus and/or
  • intracellular parasite in view of the suppression of any potential infection of protozoa and the prevention of any secondary infection. Further, the application to vaginitis and pneumonia caused by the pathogen of fungus and/or intracellular parasite for the purpose as described above is also included in the scope of the present invention.
  • composition of the present invention can be preferably exemplified, for example, by administration by inhalation, intravaginal administration, endorectal administration, oral administration, and intravascular administration. In particular, it is especially preferable to perform
  • administration as described above can be preferably exemplified, for example, by suppository, tablet, injection agent, and granule.
  • Suppository and tablet can be
  • the pharmaceutical preparation as described above may be produced by treating the essential components as described above and the components for the
  • the preferred amount of administration of the pharmaceutical composition of the present invention differs depending on, for example, the agent form, the age of patient, the body weight, and the sexuality. However, the amount of administration is preferably 10 to 5000 mg per one person per a day, while the amount is converted into the amount of the compound of the general formula (1) . It is preferable that the
  • administration is performed once a day or several times a day in a divided manner.
  • the methods for producing the suppository and the tablet will be described in detail below .
  • the suppository it is possible to apply any one of the oily suppository and the aqueous suppository.
  • the oily suppository it is possible to use hard fat including, for example, Witepsol H series, Witepsol W series, Witepsol S series, Witepsol E series (each of which is produced by Cremer Oleo & Sasol) , Pharmasol A series, Pharmasol B series, Pharmasol N series (each of which is produced by NOF Corporation) , and Isocacao M series (each of which is produced by Kao Corporation) to which Vaseline, liquid paraffin, and/or oil such as olive oil is/are added so that, the melting point is adjusted to prepare a base material.
  • the compound represented by the general formula (1) which is dissolved in crotamiton, may be dispersed therein, followed by being molded by being charged into a mold in a heated and softened state.
  • aqueous suppository polyethylene glycols having different average molecular weights are heated and mixed, and the hardness is adjusted.
  • (1) which is dissolved in crotamiton, may be dispersed therein, followed by being molded by being charged into a mold in a heated and softened state.
  • the melting point is adjusted to 33 to 36°C.
  • the melting point is adjusted to 35 to 39°C.
  • the tablet can be prepared as follows. That is, an excipient such as lactose, starch, carmellose,
  • croscarmellose or the like and a binding agent such as hydroxypropyl cellulose, gum arabic, xanthan gum or the like are mixed with each other, which is subjected to the coating with the compound represented by the general formula (1) dissolved in crotamiton, followed by performing a tablet making process and, if desired, being coated with, for example, hydroxypropyl cellulose, sucrose or the like.
  • effervescent base material such as base component comprising sodium hydrogen carbonate, sodium carbonate, magnesium
  • MIC minimum growth inhibitory concentration
  • the minimum growth inhibitory concentration (MIC; ⁇ g/mL) was designated as the minimum concentration of the compound at which the growth inhibition of 80% was
  • Trichomonas vaginalis The effect for Trichomonas vaginalis was investigated in relation to luliconazole and lanoconazole. That is, 5 x 10 6 cells of clinically isolated Trichomonas vaginalis were seeded in Trichomonas medium F (6.5 mL, contained in tube) produced by Fuj iyakuhin Co., Ltd. containing Neutral Red as a marker, and the preculture was carried out for 72 hours. It was confirmed that Trichomonas grew, the acid was actively produced, and Neutral Red was changed to be yellow. After that, the preculture was added to Trichomonas medium F (6.5 mL, contained in tube) produced by Fuj iyakuhin Co., Ltd. containing Neutral Red as a marker, and the preculture was carried out for 72 hours. It was confirmed that Trichomonas grew, the acid was actively produced, and Neutral Red was changed to be yellow. After that, the preculture was added to
  • Trichomonas medium F by every 100 ⁇ ⁇ , to which 0.5 mL of a test solution was added.
  • the number of protozoans in the solution of preculture was 1.5 x 10 5 cells/mL.
  • 0.5 mL of vehicle was added as a control.
  • 10% methanol saline solution was used as for the vehicle.
  • MIC of luliconazole was 3.2 ⁇ g/mL
  • MIC of lanoconazole was 6.4 ⁇ / ⁇ .
  • Chlamydia trachomatis (D/UW3/Cx) . That is, Chlamydia trachomatis was cultured in the presence of x2 dilution series of 8 to 64 ⁇ g/mL of luliconazole by using HeLa 229 cells as the host. MEM added with 8% thermally inactivated FBS, to which 1 ⁇ g/mL of
  • Chlamydia inclusion bodies were fluorescently stained as apple green with FITC-labeled anti-Chlamydia monoclonal antibody "Chlamydia Kit F" (DENKA SEIKEN Co., Ltd.), and the observation was performed by using a fluorescence microscope. The concentration, at which the fluorescent color of apple green was not observed at all, was designated as MIC. MIC of luliconazole with respect to Chlamydia trachomatis was 32 ⁇ g/mL.
  • Trichomonas vaginalis (clinically isolated strain) was used to investigate the effect of crotamiton on luliconazole .
  • Luliconazole was dissolved in 0.5 mL of 10% ethanol solution together with crotamiton, followed by being added to "Trichomonas medium F" (produced by Fuji Pharma Co., Ltd.) to which 100 ⁇ , of a culture medium of 1 x 10 5 cells/mL of Trichomonas vaginalis was added.
  • the cultivation was carried out at 37°C for 72 hours, followed by being cooled for 5 minutes with ice water. After that, the number of Trichomonas vaginalis cells in the medium was counted by using a hemocytometer . Results are shown in Table 2. Accordingly, it is appreciated that the coexistence of crotamiton enhances the effect of luliconazole against Trichomonas .
  • a vaginal suppository was manufactured in accordance with a formulation shown below. 'That is, components of A were heated and dissolved. A preparation, which was obtained by heating and dissolving components of B, was gradually added thereto while stirring, thereby being dispersed. Stirring and cooling were performed until arrival at 60°C, followed by being poured into a mold. Cooling was performed spontaneously, followed by being solidified to obtain the vaginal suppository.
  • a vaginal suppository was prepared in accordance with a formulation shown below in the same manner as in Example 3. .
  • a rectal suppository was manufactured in accordance with a formulation shown below in the same manner as in Example 3. [0043]
  • a rectal suppository was manufactured in accordance with a formulation shown below in the same manner as in Example 3.
  • a tablet was prepared in accordance with a formulation shown below. That is, components of A were sufficiently mixed, to which solubilized components of B were sprayed to coat the components of A. A ' component of C was mixed therewith,, followed by being humidified and granulated. Blowing and drying were performed at 40°C to manufacture granules which were subjected to the tablet making to obtain the tablet.
  • the tablet was preferred as a vaginal tablet and an oral tablet.
  • a tablet was manufactured in the same manner as in Example 7.
  • a vaginal suppository was prepared in accordance with a formulation shown below in the same manner as in Example 3.
  • a vaginal suppository was prepared in accordance with a formulation shown below in the same manner as in Example 3.
  • a vaginal suppository was prepared in accordance with a formulation shown below in the same manner as in Example 3.
  • a vaginal suppository was prepared in accordance with a formulation shown below in the same manner as in Example 3. [0057]
  • a vaginal suppository was prepared in accordance with a formulation shown below in the same manner as, in Example 3.
  • a vaginal suppository was prepared in accordance with a formulation shown below in the same manner as in Example 3.
  • An effervescent tablet was manufactured in accordance with a formulation shown below with a direct tableting method. That tablet was preferred as a vaginal
  • An effervescent tablet was prepared in accordance with a formulation shown below in the same manner as in Example 11. [0065]
  • Lactose 55 Dried sodium hydrogen carbonate 24 Anhydrous citric acid 14 Carmellose ' 5
  • the present invention is applicable to

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique dans laquelle l'action d'un composé représenté par la formule (1) est améliorée, et qui est efficace en cas de pneumonie et de vaginite. L'invention concerne une composition pharmaceutique pour traiter une vaginite ou une pneumonie, comprenant un composé représenté par la formule (1) et un crotamiton. Dans la formule (1), chacun de R1 et R2 représente indépendamment un atome d'hydrogène et un atome halogène, et R1 et R2 ne sont pas simultanément des atomes d'hydrogène.
PCT/JP2014/063138 2013-05-17 2014-05-13 Composition pharmaceutique pour traiter une vaginite ou une pneumonie WO2014185542A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015551899A JP2016518306A (ja) 2013-05-17 2014-05-13 アスペルギルス、カンジダ等を病原体とする疾患用の医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-104866 2013-05-17
JP2013104866 2013-05-17

Publications (1)

Publication Number Publication Date
WO2014185542A1 true WO2014185542A1 (fr) 2014-11-20

Family

ID=50877625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/063138 WO2014185542A1 (fr) 2013-05-17 2014-05-13 Composition pharmaceutique pour traiter une vaginite ou une pneumonie

Country Status (2)

Country Link
JP (1) JP2016518306A (fr)
WO (1) WO2014185542A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015076352A1 (fr) * 2013-11-19 2015-05-28 Pola Pharma Inc. Composition pharmaceutique pour le traitement d'une pneumonie associée à fusarium fungus
CN105902539A (zh) * 2016-03-31 2016-08-31 宝丽制药股份有限公司 抗三毛滴虫剂
US9453006B2 (en) 2013-03-08 2016-09-27 Pola Pharma Inc. Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
US9527836B2 (en) 2013-09-06 2016-12-27 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108934161A (zh) * 2017-03-29 2018-12-04 日本农药株式会社 用于治疗感染症的医药组合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60218387A (ja) 1984-04-14 1985-11-01 Nippon Nohyaku Co Ltd ケテンｓ，ｓ−アセタ−ル類
JPH08198773A (ja) 1995-01-24 1996-08-06 Hideyo Yamaguchi 抗真菌剤
JP2002514165A (ja) 1996-07-12 2002-05-14 アリアド・ファーマシューティカルズ・インコーポレイテッド 病原性真菌感染の治療または予防材料および方法
JP2003527308A (ja) 1998-12-04 2003-09-16 インフラックス，インコーポレイテッド 多剤輸送体の阻害剤
JP2004521102A (ja) 2001-01-09 2004-07-15 メルク　エンド　カムパニー　インコーポレーテッド 抗真菌化合物の活性代謝物
WO2007102242A1 (fr) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. Composition pharmaceutique externe
JP2008156346A (ja) * 2006-11-29 2008-07-10 Rohto Pharmaceut Co Ltd 抗真菌医薬組成物
WO2011155640A1 (fr) * 2010-06-11 2011-12-15 Pola Pharma Inc. Composition pharmaceutique antimycosique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5953882B2 (ja) * 1978-09-18 1984-12-27 宇津救命丸株式会社 抗カンジダ剤
JP5033605B2 (ja) * 2007-12-05 2012-09-26 セーレン株式会社 口腔ケア用組成物
JP5743375B2 (ja) * 2008-09-30 2015-07-01 小林製薬株式会社 カンジダ症予防又は治療剤
WO2010093992A1 (fr) * 2009-02-13 2010-08-19 Topica Pharmaceuticals, Inc Formulation antifongique
JP2012144449A (ja) * 2011-01-07 2012-08-02 Nippon Nohyaku Co Ltd ルリコナゾールの皮膚浸透性を向上させる配合処方

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60218387A (ja) 1984-04-14 1985-11-01 Nippon Nohyaku Co Ltd ケテンｓ，ｓ−アセタ−ル類
JPH08198773A (ja) 1995-01-24 1996-08-06 Hideyo Yamaguchi 抗真菌剤
JP2002514165A (ja) 1996-07-12 2002-05-14 アリアド・ファーマシューティカルズ・インコーポレイテッド 病原性真菌感染の治療または予防材料および方法
JP2003527308A (ja) 1998-12-04 2003-09-16 インフラックス，インコーポレイテッド 多剤輸送体の阻害剤
JP2004521102A (ja) 2001-01-09 2004-07-15 メルク　エンド　カムパニー　インコーポレーテッド 抗真菌化合物の活性代謝物
WO2007102242A1 (fr) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. Composition pharmaceutique externe
EP2005958A1 (fr) * 2006-03-08 2008-12-24 Nihon Nohyaku Co., Ltd. Composition pharmaceutique externe
JP2008156346A (ja) * 2006-11-29 2008-07-10 Rohto Pharmaceut Co Ltd 抗真菌医薬組成物
WO2011155640A1 (fr) * 2010-06-11 2011-12-15 Pola Pharma Inc. Composition pharmaceutique antimycosique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200856, Derwent World Patents Index; AN 2008-J58532, XP002729302 *
MITTAL A; RASTOGI S; REDDY BS; VERMA S; SALHAN S; GUPTA E: "Enhanced immunocompetent cells in chlamydial cervicitis.", J REPROD MED., vol. 49, no. 8, 2004, pages 671 - 7
NIWANO YOSHIMI ET AL: "Lanoconazole and its related optically active compound NND-502: Novel antifungal imidazoles with a ketene dithioacetal structure", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBL, NL, vol. 2, no. 2, 1 June 2003 (2003-06-01), pages 147 - 160, XP008167849, ISSN: 1568-0126, DOI: 10.2174/1568012033483097 *
PAL C; BANDYOPADHYAY U.: "Redox-active antiparasitic drugs", ANTIOXID REDOX SIGNAL., vol. 17, no. 4, 2012, pages 555 - 82
ZDRODOWSKA-STEFANOW B; KLOSOWSKA WM; OSTASZEWSKA-PUCHALSKA I; BULHAK-KOZIOL V; KOTOWICZ B: "Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases.", ADV MED SCI., vol. 51, 2006, pages 250 - 3

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453006B2 (en) 2013-03-08 2016-09-27 Pola Pharma Inc. Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
US9527836B2 (en) 2013-09-06 2016-12-27 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient
WO2015076352A1 (fr) * 2013-11-19 2015-05-28 Pola Pharma Inc. Composition pharmaceutique pour le traitement d'une pneumonie associée à fusarium fungus
CN105902539A (zh) * 2016-03-31 2016-08-31 宝丽制药股份有限公司 抗三毛滴虫剂
WO2017168476A1 (fr) * 2016-03-31 2017-10-05 Pola Pharma Inc. Agent anti-tritrichomonas

Also Published As

Publication number Publication date
JP2016518306A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
WO2014185542A1 (fr) Composition pharmaceutique pour traiter une vaginite ou une pneumonie
KR101751726B1 (ko) 특이한 정벽을 가지는 결정형 및 이 결정형을 유효 성분으로서 함유하는 약학 조성물
Zhang et al. Design, synthesis, and biological evaluation of novel benzimidazole derivatives and their interaction with calf thymus DNA and synergistic effects with clinical drugs
US20150266827A1 (en) Antibiotic Tolerance Inhibitors
WO2013052263A2 (fr) Composés antifongiques
CN110407898B (zh) 具有提高的治疗指数的两性霉素b衍生物
JP2017527594A (ja) コアクチベーター関連アルギニンメチルトランスフェラーゼ１（ｃａｒｍ１）阻害剤の塩、共結晶、非晶質形態、および結晶形態
CN104086534B (zh) 喹诺酮唑醇类化合物及其制备方法和应用
JP6279583B2 (ja) アスペルギルス等の病原微生物による疾患用の医薬組成物
JP6254597B2 (ja) カンジダ等の病原微生物による疾患用の医薬組成物
JP6726192B2 (ja) アムホテリシンｂの尿素誘導体の簡便な合成法
US20080161249A1 (en) Use of Novel Antibacterial Compounds
CN1970552A (zh) 取代[1,3,5]三嗪类化合物及其制备方法和应用
CN103819464B (zh) 硫色满类化合物及其合成方法和制备抗真菌药物的应用
CN105294661B (zh) 5‑氟尿嘧啶苯并咪唑类化合物及其制备方法和应用
CN101633655B (zh) 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
Murtiastutik et al. Epigallocathecingallate (EGCG) antifungal properties for Candida isolates from HIV/AIDS patients with oral candidiasis in compare with fluconazole
Curvelo et al. 3-Indol carboxaldehyde, an imidazole synthesized from naphthoquinone β-lapachone downregulates Candida albicans biofilm
RU2595852C1 (ru) Антимикробные суппозитории
KR20150008989A (ko) 봉독 정제물을 포함하는 질염 예방 및 치료용 조성물
CN102060793B (zh) 具生物活性的双芳基叔胺唑类化合物及制备方法和医药用途
CN101759692B (zh) 硫代羰基化合物及其药物用途
RU2504541C1 (ru) 2-нитрогетерилтиоцианаты для лечения грибковых инфекций, фармацевтическая композиция для местного применения
RU2536273C1 (ru) Средство ухода за кожей, обладающее антифунгальными свойствами
Łukaszuk et al. In vitro antifungal activity of new thiatriazole derivative agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14727634

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015551899

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14727634

Country of ref document: EP

Kind code of ref document: A1